# Letrozole

## Femara 2.5mg

| 藥物代碼 | OFEM |
| :--- | :--- |
| 適應症 | Treatment of advanced breast cancer in women with natural or artificially induced postmenopausal status, who have previously been treated with antioestrogens. 1st-line treatment in postmenopausal women with hormone-dependent advanced breast cancer. Extended adjuvant treatment of hormone receptor +ve & LN metastasis +ve breast cancer patient who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor +ve invasive early breast cancer. |
| 副作用 | Headache, nausea, peripheral edema, fatigue, hot flushes.Cardiovascular: Edema \(7.2% to 18.4% \)Dermatologic: Hot sweats \(5% to 49.7% \), Sweating \(up to 24.2% \)Gastrointestinal: Constipation \(1.5% to 11.3% \), Diarrhea \(5% to 8% \), Loss of appetite \(3% to 5% \), Nausea \(8.6% to 17% \), Vomiting \(2.7% to 7% \)Musculoskeletal: Arthralgia \(8% to 22% \), Arthritis \(6.7% to 21.1%\), Backache \(5% to 18% \), Bone pain \(22% \), Myalgia \(6.4% to 6.7% \)Neurologic: Asthenia \(4% to 33.6% \), Dizziness \(2.4% to 14.2% .\), Headache \(3.5% to 20.1% \), Insomnia \(5.8% to 7% .\), Somnolence \(2% to 3% .\)Respiratory: Dyspnea \(5.5% to 18% \)Other: Fatigue \(6% to 13% \) |
| 禁忌 | Hypersensitivity to letrozole or any component of the formulation; pregnancy. Use in patients &lt;18 years of age; premenopausal endocrine status; breastfeeding. |
| 藥物保存方式 | 室溫 |
| 用法用量 | 2.5 mg once daily. |
| 肝功能異常 | 無需調整劑量  Child-Pugh C密切監控 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | Contraindicated |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

